FI111730B - Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi - Google Patents
Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi Download PDFInfo
- Publication number
- FI111730B FI111730B FI915135A FI915135A FI111730B FI 111730 B FI111730 B FI 111730B FI 915135 A FI915135 A FI 915135A FI 915135 A FI915135 A FI 915135A FI 111730 B FI111730 B FI 111730B
- Authority
- FI
- Finland
- Prior art keywords
- meleu
- cyclosporin
- ciclosporin
- mebmt
- hydroxy
- Prior art date
Links
- 229930182912 cyclosporin Natural products 0.000 title claims abstract description 59
- 108010036941 Cyclosporins Proteins 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims description 19
- 230000001506 immunosuppresive effect Effects 0.000 title claims description 17
- 238000000034 method Methods 0.000 title claims description 17
- 230000008569 process Effects 0.000 title claims description 10
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 69
- 229960001265 ciclosporin Drugs 0.000 claims description 107
- 150000001875 compounds Chemical class 0.000 claims description 90
- 108010036949 Cyclosporine Proteins 0.000 claims description 63
- 229930105110 Cyclosporin A Natural products 0.000 claims description 38
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 claims description 28
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical group CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 claims description 23
- AHQFCPOIMVMDEZ-UNISNWAASA-N (e,2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid Chemical group CN[C@H](C(O)=O)[C@H](O)[C@H](C)C\C=C\C AHQFCPOIMVMDEZ-UNISNWAASA-N 0.000 claims description 21
- 239000001963 growth medium Substances 0.000 claims description 14
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- 241001149960 Tolypocladium inflatum Species 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 5
- 241000921533 Nonomuraea dietziae Species 0.000 claims description 4
- 230000000640 hydroxylating effect Effects 0.000 claims description 3
- 238000004362 fungal culture Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 102000001493 Cyclophilins Human genes 0.000 abstract description 11
- 108010068682 Cyclophilins Proteins 0.000 abstract description 11
- 208000030507 AIDS Diseases 0.000 abstract description 9
- 208000037859 AIDS-related disorder Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 30
- 239000000243 solution Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- DFZMWWCBMPCKFD-DTLHCQOUSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacon Chemical compound CC[C@@H]1NC(=O)C([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)CN(C)C1=O DFZMWWCBMPCKFD-DTLHCQOUSA-N 0.000 description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000006257 total synthesis reaction Methods 0.000 description 5
- GBIWPCXWDSDANU-JYFGSSRXSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,18,19,25,28-decamethyl-6,9,24-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,2 Chemical compound CC[C@@H]1NC(=O)C([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O GBIWPCXWDSDANU-JYFGSSRXSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000036983 biotransformation Effects 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 4
- 235000011149 sulphuric acid Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- -1 γ-hydroxy-MeLeu Chemical class 0.000 description 4
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 108010019249 cyclosporin G Proteins 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 108010019248 cyclosporin C Proteins 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940032085 sucrose monolaurate Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- GEUKOOCPPICVTB-SMOCYEBVSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32- Chemical compound CCCC[C@@H](C)[C@@H](O)C1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O GEUKOOCPPICVTB-SMOCYEBVSA-N 0.000 description 1
- ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 description 1
- DFZMWWCBMPCKFD-UHFFFAOYSA-N (gamma-OH)MeLeu4-Cs Natural products CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)(C)O)N(C)C(=O)CN(C)C1=O DFZMWWCBMPCKFD-UHFFFAOYSA-N 0.000 description 1
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101000908859 Arabidopsis thaliana Peptidyl-prolyl cis-trans isomerase CYP18-4 Proteins 0.000 description 1
- 238000011749 CBA mouse Methods 0.000 description 1
- 101000921797 Caenorhabditis elegans Peptidyl-prolyl cis-trans isomerase 1 Proteins 0.000 description 1
- 101000921794 Caenorhabditis elegans Peptidyl-prolyl cis-trans isomerase 10 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
- 229930182822 D-threonine Natural products 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000921923 Glycine max Peptidyl-prolyl cis-trans isomerase 1 Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000878213 Homo sapiens Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100036984 Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001134635 Micromonosporaceae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- FYCWLJLGIAUCCL-DMTCNVIQSA-N O-methyl-L-threonine Chemical compound CO[C@H](C)[C@H](N)C(O)=O FYCWLJLGIAUCCL-DMTCNVIQSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 241001330507 Sebekia Species 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- PUZCUNCKTTTWOS-UHFFFAOYSA-N [Sn].CC(=O)C Chemical compound [Sn].CC(=O)C PUZCUNCKTTTWOS-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- ANUZKYYBDVLEEI-UHFFFAOYSA-N butane;hexane;lithium Chemical compound [Li]CCCC.CCCCCC ANUZKYYBDVLEEI-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- QHFQAJHNDKBRBO-UHFFFAOYSA-L calcium chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ca+2] QHFQAJHNDKBRBO-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 108010019594 cyclosporin D Proteins 0.000 description 1
- 108010019251 cyclosporin H Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 108010040781 dihydrocyclosporin D Proteins 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909023859A GB9023859D0 (en) | 1990-11-02 | 1990-11-02 | Chemical products |
| GB9023859 | 1990-11-02 | ||
| GB9023970 | 1990-11-05 | ||
| GB909023971A GB9023971D0 (en) | 1990-11-05 | 1990-11-05 | New use of a cyclosporin derivative |
| GB909023970A GB9023970D0 (en) | 1990-11-05 | 1990-11-05 | New use of a cyclosporin derivative |
| GB9023972 | 1990-11-05 | ||
| GB9023971 | 1990-11-05 | ||
| GB909023972A GB9023972D0 (en) | 1990-11-05 | 1990-11-05 | New use of a cyclosporin derivative |
| GB9116836 | 1991-08-05 | ||
| GB919116836A GB9116836D0 (en) | 1991-08-05 | 1991-08-05 | Organic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI915135A0 FI915135A0 (fi) | 1991-10-30 |
| FI915135L FI915135L (fi) | 1992-05-03 |
| FI111730B true FI111730B (fi) | 2003-09-15 |
Family
ID=27517009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI915135A FI111730B (fi) | 1990-11-02 | 1991-10-30 | Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US5767069A (en:Method) |
| EP (1) | EP0484281B2 (en:Method) |
| JP (1) | JP2740775B2 (en:Method) |
| KR (1) | KR100203556B1 (en:Method) |
| AT (1) | ATE148469T1 (en:Method) |
| AU (1) | AU649277B2 (en:Method) |
| CA (1) | CA2054590C (en:Method) |
| CY (1) | CY2159B1 (en:Method) |
| CZ (1) | CZ280909B6 (en:Method) |
| DE (1) | DE69124459T3 (en:Method) |
| DK (1) | DK0484281T4 (en:Method) |
| ES (1) | ES2095926T5 (en:Method) |
| FI (1) | FI111730B (en:Method) |
| GR (2) | GR3022592T3 (en:Method) |
| HU (1) | HU212674B (en:Method) |
| IE (1) | IE913824A1 (en:Method) |
| IL (1) | IL99912A (en:Method) |
| MX (1) | MX9101869A (en:Method) |
| MY (1) | MY134806A (en:Method) |
| NZ (1) | NZ240421A (en:Method) |
| PL (1) | PL168609B1 (en:Method) |
| PT (1) | PT99410B (en:Method) |
| SA (1) | SA92120344B1 (en:Method) |
| SK (1) | SK278808B6 (en:Method) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993014780A1 (en) * | 1992-01-28 | 1993-08-05 | Abraham Karpas | The use of a compound for the manufacture of a medicament for the treatment of hiv infection |
| GB9204466D0 (en) * | 1992-03-02 | 1992-04-15 | Sandoz Ltd | Improvements in or relating to organic compounds |
| ES2065273B1 (es) * | 1993-05-25 | 1995-09-16 | Biogal Gyogyszergyar | Procedimiento para la purificacion de ciclosporina a. |
| US5639852A (en) * | 1994-09-01 | 1997-06-17 | Wisconsin Alumni Research Foundation | Immunostimulatory agents |
| US5948693A (en) * | 1994-09-01 | 1999-09-07 | Wisconsin Alumni Research Foundation | Solid phase synthesis of immunosuppressive agents |
| US6696413B2 (en) | 1995-06-16 | 2004-02-24 | Hexal Ag | Pharmaceutical preparation with cyclosporin A |
| CN1141317C (zh) * | 1995-07-17 | 2004-03-10 | 碳化学公司 | 有抗人体免疫缺损病毒作用的环孢菌素衍生物 |
| JP3089350B2 (ja) * | 1995-11-20 | 2000-09-18 | ギルフォード ファーマシューティカルズ インコーポレイテッド | シクロフィリンロタマーゼ活性の阻害剤 |
| EP0944394A4 (en) * | 1996-03-12 | 2003-05-14 | Picower Inst Med Res | TREATING HIV INFECTION BY INFLUENCING CYCLOPHILIN RECEPTOR ACTIVITY IN THE HOST CELL |
| CN1130373C (zh) * | 1996-09-13 | 2003-12-10 | 诺瓦蒂斯有限公司 | [3'－脱氧－3'－氧代－MeBmt]'环孢菌素制备方法 |
| FR2757522B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757521B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757520B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
| FR2762843B1 (fr) * | 1997-04-30 | 1999-12-10 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| DE69840586D1 (de) | 1997-10-08 | 2009-04-02 | Isotechnika Inc | Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien |
| US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| ZA99981B (en) * | 1998-02-17 | 2000-08-08 | Du Pont Pharm Co | Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors. |
| GB9811854D0 (en) * | 1998-06-02 | 1998-07-29 | Ciba Geigy Ag | Organic compounds |
| FR2780061B1 (fr) | 1998-06-22 | 2001-09-07 | Rhone Poulenc Rorer Sa | Nouveau procede de preparation de derives de cyclosporine |
| AU759480B2 (en) * | 1998-07-01 | 2003-04-17 | Debiopharm S.A. | Novel cyclosporin with improved activity profile |
| CA2358448C (en) | 1998-12-30 | 2009-02-10 | Dexcel Ltd. | Dispersible concentrate for the delivery of cyclosporin |
| US6521595B1 (en) * | 1999-11-19 | 2003-02-18 | Lg Chemical, Ltd. | Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| US6995139B2 (en) * | 2001-04-20 | 2006-02-07 | Debiopharm S.A. | Cyclic undecapeptide pro-drugs and uses thereof |
| KR100695611B1 (ko) * | 2001-05-17 | 2007-03-14 | 주식회사 엘지생활건강 | [감마 히드록시 엔-메틸 엘-루신4] 사이클로스포린유도체를 유효성분으로 하는 모발 성장 촉진제 |
| RU2321593C9 (ru) | 2001-10-19 | 2008-06-20 | Изотехника Инк. | Синтез аналогов циклоспорина |
| PL206018B1 (pl) * | 2001-10-19 | 2010-06-30 | Isotechnika Inc | Preparat farmaceutyczny, sposób jego wytwarzania, mikroemulsja i zastosowanie tego preparatu farmaceutycznego |
| WO2003038032A2 (de) * | 2001-10-25 | 2003-05-08 | Viromics Gmbh | Mittel zur hemmung der synthese von virusproteinen |
| US7108988B2 (en) * | 2001-11-02 | 2006-09-19 | The J. David Gladstone Institutes | Methods of identifying agents for inhibiting lentivirus replication |
| JP2006524232A (ja) | 2003-03-17 | 2006-10-26 | アルバニー モレキュラー リサーチ インコーポレーティッド | 新規サイクロスポリン |
| GB0320638D0 (en) * | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| EP1742652A2 (en) * | 2004-04-08 | 2007-01-17 | Novartis AG | Use of cyclosporins for treatment of cerebral ischemia and brain and spinal cord injury |
| EP1893226A1 (en) * | 2004-07-13 | 2008-03-05 | Novartis AG | Cyclosporins to treat alzheimer's disease |
| US7671017B2 (en) | 2004-07-14 | 2010-03-02 | Novartis Ag | Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV) |
| KR100597309B1 (ko) | 2004-09-17 | 2006-07-05 | 주식회사 핸슨바이오텍 | 세베키아 베니하나를 이용한 [감마 히드록실메틸루신4] 사이클로스포린 a의 제조방법 |
| EP1809656A4 (en) * | 2004-09-29 | 2009-03-25 | Amr Technology Inc | CYCLOSPORINAL KINANALOGA AND ITS PHARMACEUTICAL APPLICATIONS |
| WO2006039164A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
| CA2583494C (en) * | 2004-10-01 | 2014-01-21 | Scynexis, Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection |
| US7196161B2 (en) * | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| US7361636B2 (en) * | 2004-10-06 | 2008-04-22 | Amr Technology, Inc. | Cyclosporin alkynes and their utility as pharmaceutical agents |
| US7135455B2 (en) * | 2004-11-15 | 2006-11-14 | Allergan, Inc | Methods for the therapeutic use of cyclosporine components |
| US7151085B2 (en) * | 2004-11-15 | 2006-12-19 | Allergan, Inc. | Therapeutic methods using cyclosporine components |
| KR100777488B1 (ko) | 2004-12-15 | 2007-11-28 | 주식회사 핸슨바이오텍 | 세베키아 베니하나 (Sebekia benihana)배양물로부터 감마-히드록실메틸루신4 사이클로스포린 A를 효과적이고 선택적으로 회수하는 방법 |
| KR20070089954A (ko) * | 2004-12-23 | 2007-09-04 | 노파르티스 아게 | 플라비비리대 치료용 화합물 |
| RU2007128099A (ru) | 2004-12-23 | 2009-01-27 | Новартис АГ (CH) | Композиции для лечения гепатита с |
| JP5322647B2 (ja) * | 2005-09-30 | 2013-10-23 | スシネキス インク | ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体 |
| US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| EP2007789B1 (en) | 2006-04-11 | 2015-05-20 | Novartis AG | Spirocyclic HCV/HIV inhibitors and their uses |
| ATE502633T1 (de) | 2006-05-19 | 2011-04-15 | Scynexis Inc | Cyclosporins zur behandlung und vorbeugung von augenerkrankungen |
| CN101502196A (zh) * | 2006-06-02 | 2009-08-05 | 克洛德·安妮·佩里西恩 | 激活电子的管理 |
| US7576057B2 (en) * | 2006-11-20 | 2009-08-18 | Scynexis, Inc. | Cyclic peptides |
| WO2008127613A1 (en) * | 2007-04-11 | 2008-10-23 | Scynexis, Inc. | New pharmaceutical compositions |
| NZ584356A (en) * | 2007-09-26 | 2011-10-28 | Univ Oregon Health & Science | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
| CN102083852A (zh) * | 2008-06-06 | 2011-06-01 | 西尼克斯公司 | 环孢菌素类似物及其在治疗hcv感染中的应用 |
| JP5726733B2 (ja) * | 2008-07-30 | 2015-06-03 | シクロフィリン ファーマシューティカルズ コープ． | 非免疫抑制性シクロスポリン類似体分子 |
| JP5780969B2 (ja) | 2008-12-31 | 2015-09-16 | サイネクシス，インコーポレーテッド | シクロスポリンａの誘導体 |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| US8481483B2 (en) * | 2009-02-19 | 2013-07-09 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| GB0909754D0 (en) * | 2009-06-05 | 2009-07-22 | Magnani Mauro | Drug delivery systems |
| EP2516387B1 (en) * | 2009-12-21 | 2018-02-21 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Inhibitors of cyclophilins for use in the prevention and/or the treatment of viral pathologies or infections |
| KR20120125610A (ko) | 2009-12-30 | 2012-11-16 | 싸이넥시스, 인크. | 시클로스포린 유사체 |
| WO2012009715A2 (en) | 2010-07-16 | 2012-01-19 | S&T Global Inc. | Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
| CN103153330B (zh) | 2010-08-12 | 2017-08-18 | 美国科技环球有限公司 | 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用 |
| CN103179966B (zh) | 2010-10-08 | 2017-03-15 | 诺瓦提斯公司 | 磺酰胺ns3抑制剂的维生素e制剂 |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9890198B2 (en) | 2010-12-03 | 2018-02-13 | S&T Global Inc. | Cyclosporin derivatives and uses thereof |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| HRP20190096T1 (hr) | 2010-12-15 | 2019-02-22 | Contravir Pharmaceuticals, Inc. | Molekule analoga ciklosporina modificirani na amino kiselini 1 i 3 |
| US20120253007A1 (en) * | 2011-03-28 | 2012-10-04 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Synthesis of Cyclosporin H |
| US20140205566A1 (en) | 2012-11-30 | 2014-07-24 | Novartis Ag | Cyclic nucleuoside derivatives and uses thereof |
| US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| US20160361322A1 (en) | 2015-06-15 | 2016-12-15 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| JP2020503269A (ja) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | 経口ウンデカン酸テストステロン療法 |
| EP3824296A4 (en) | 2018-07-20 | 2022-04-27 | Lipocine Inc. | LIVER DISEASE |
| CN111449050A (zh) | 2019-01-20 | 2020-07-28 | 睿诺医疗科技（上海）有限公司 | 环孢菌素类似物及其用途 |
| TWI887279B (zh) | 2019-10-12 | 2025-06-21 | 大陸商睿諾醫療科技（上海）有限公司 | 腎毒素引起的腎損傷的治療和預防 |
| CA3172601A1 (en) | 2020-03-26 | 2021-09-30 | Ching-Pong Mak | Preparation of cyclosporin derivatives |
| JP2023521161A (ja) | 2020-04-15 | 2023-05-23 | ファーサイト メディカル テクノロジー （シャンハイ） カンパニー リミテッド | 臓器傷害の予防及び処置 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2455859C2 (de) | 1973-12-06 | 1983-12-15 | Sandoz-Patent-GmbH, 7850 Lörrach | Das Antibiotikum Cyclosporin A (S 7481/F-1), seine Herstellung und Verwendung |
| US4304855A (en) * | 1977-05-05 | 1981-12-08 | The Upjohn Company | Allylic methyl-hydroxylated novobiocins |
| CH667274A5 (de) * | 1984-03-23 | 1988-09-30 | Sandoz Ag | Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
| EP0194972B1 (en) * | 1985-03-11 | 1992-07-29 | Sandoz Ag | Novel cyclosporins |
| US4814323A (en) * | 1986-03-25 | 1989-03-21 | Andrieu J M | Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus |
| EP0283801A3 (en) * | 1987-03-27 | 1990-05-30 | Abbott Laboratories | Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies |
| US4798823A (en) * | 1987-06-03 | 1989-01-17 | Merck & Co., Inc. | New cyclosporin analogs with modified "C-9 amino acids" |
| EP0373260B1 (en) * | 1987-06-22 | 1994-03-09 | Merck & Co. Inc. | Cyclosporin derivatives with modified "8-amino acid" |
| GB8717300D0 (en) * | 1987-07-22 | 1987-08-26 | Nat Res Dev | Cyclosporins |
| US4981799A (en) * | 1987-08-21 | 1991-01-01 | Takeda Chemical Industries, Ltd. | Acylamino acid racemase, production and use thereof |
| US4914188A (en) † | 1987-11-16 | 1990-04-03 | Merck & Co., Inc. | Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin |
| US5081024A (en) * | 1988-09-05 | 1992-01-14 | Nissan Chemical Industries, Ltd. | Process for producing optically active amino acids |
| US5122511A (en) * | 1990-02-27 | 1992-06-16 | Merck & Co., Inc. | Immunosuppressive cyclosporin analogs with modified amino acids at position-8 |
-
1991
- 1991-10-30 DE DE69124459T patent/DE69124459T3/de not_active Expired - Lifetime
- 1991-10-30 SK SK3297-91A patent/SK278808B6/sk not_active IP Right Cessation
- 1991-10-30 EP EP91810841A patent/EP0484281B2/en not_active Expired - Lifetime
- 1991-10-30 FI FI915135A patent/FI111730B/fi not_active IP Right Cessation
- 1991-10-30 ES ES91810841T patent/ES2095926T5/es not_active Expired - Lifetime
- 1991-10-30 DK DK91810841T patent/DK0484281T4/da active
- 1991-10-30 CZ CS913297A patent/CZ280909B6/cs not_active IP Right Cessation
- 1991-10-30 AT AT91810841T patent/ATE148469T1/de not_active IP Right Cessation
- 1991-10-31 AU AU86923/91A patent/AU649277B2/en not_active Expired
- 1991-10-31 NZ NZ240421A patent/NZ240421A/en not_active IP Right Cessation
- 1991-10-31 PL PL91292248A patent/PL168609B1/pl unknown
- 1991-10-31 CA CA002054590A patent/CA2054590C/en not_active Expired - Lifetime
- 1991-10-31 PT PT99410A patent/PT99410B/pt not_active IP Right Cessation
- 1991-10-31 IL IL9991291A patent/IL99912A/en not_active IP Right Cessation
- 1991-10-31 MX MX9101869A patent/MX9101869A/es unknown
- 1991-11-01 IE IE382491A patent/IE913824A1/en not_active IP Right Cessation
- 1991-11-01 KR KR1019910019402A patent/KR100203556B1/ko not_active Expired - Lifetime
- 1991-11-01 MY MYPI91002021A patent/MY134806A/en unknown
- 1991-11-01 JP JP3287501A patent/JP2740775B2/ja not_active Expired - Lifetime
- 1991-11-01 HU HU913446A patent/HU212674B/hu unknown
-
1992
- 1992-01-19 SA SA92120344A patent/SA92120344B1/ar unknown
-
1995
- 1995-04-24 US US08/427,312 patent/US5767069A/en not_active Expired - Lifetime
-
1997
- 1997-02-19 GR GR970400277T patent/GR3022592T3/el unknown
-
1998
- 1998-05-26 US US09/084,709 patent/US5981479A/en not_active Expired - Lifetime
-
1999
- 1999-09-09 US US09/392,282 patent/US6255100B1/en not_active Expired - Fee Related
-
2000
- 2000-01-13 CY CY0000002A patent/CY2159B1/xx unknown
-
2001
- 2001-01-31 GR GR20010400150T patent/GR3035323T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI111730B (fi) | Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi | |
| JP4350898B2 (ja) | 活性の特徴が改善された新規のシクロスポリン | |
| EP0056782B1 (en) | Novel cyclosporins | |
| US4914188A (en) | Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin | |
| CS249542B2 (en) | Method of cyclosporines production | |
| US5116816A (en) | Cyclosporin peptolides having an α-hydroxycarboxylic acid at position 8 | |
| US7538084B2 (en) | Cyclosporins | |
| CA2250630C (en) | Novel lantibiotic related to actagardine, and processes for the preparation and use thereof | |
| RU2085589C1 (ru) | Циклоспорины | |
| HK1005741B (en) | Cyclosporins | |
| NO310028B1 (no) | Cyklosporiner, deres anvendelse og fremstilling samt en biologisk ren kilde | |
| RO110144B1 (ro) | Noi ciclosporine, procedeu de sinteză a acestora și metodă de tratament și prevenire a SIDA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or assigment of application |
Owner name: NOVARTIS AG |
|
| MA | Patent expired |